Search

Abstract The huge advantages of intelligent vehicles (IVs) in improving road safety and operating efficiency have become a research focus in the industry. IVs have made significant progress in recent years, but it is still face great challenges in order to be accepted by users on a large scale. In this regard, the authors propose that the research of IVs can be developed along the lines of safety, comfort and economy, gradually overcoming existing dilemmas. First of all, security is the most basic requirement of IVs. The authors sort out the key technologies and challenges of the basic architecture of IVs, and propose existing attack and defences strategies for IVs information security technology. Secondly, comfort is more about people's subjective feelings. From two aspects of physiological comfort and psychological comfort, the paper studies the anthropomorphic decision‐making to overcome the mechanized speed control, human computer interaction design, personalized driving style and ethical decision‐making methods. Then, aiming at the micro‐ and macro‐levels of economy, it outlines technologies such as economic driving behavioural, collaborative control of people, vehicles and roads and IVs sharing. Finally, the authors summarized the challenges and future development directions in the three stages of IVs development.

Abstract Well‐defined nanostructures are crucial for precisely understanding nano‐bio interactions. However, nanoparticles (NPs) fabricated through conventional synthesis approaches often lack poor controllability and reproducibility. Herein, a synthetic biology‐based strategy is introduced to fabricate uniformly reproducible protein‐based NPs, achieving precise control over heterogeneous components of the NPs. Specifically, a ferritin assembly toolbox system is developed that enables intracellular assembly of ferritin subunits/variants in Escherichia coli. Using this strategy, a proof‐of‐concept study is provided to explore the interplay between ligand density of NPs and their tumor targets/penetration. Various ferritin hybrid nanocages (FHn) containing human ferritin heavy chains (FH) and light chains are accurately assembled, leveraging their intrinsic binding with tumor cells and prolonged circulation time in blood, respectively. Further studies reveal that tumor cell uptake is FH density‐dependent through active binding with transferrin receptor 1, whereas in vivo tumor accumulation and tissue penetration are found to be correlated to heterogeneous assembly of FHn and vascular permeability of tumors. Densities of 3.7 FH/100 nm2 on the nanoparticle surface exhibit the highest degree of tumor accumulation and penetration, particularly in tumors with high permeability compared to those with low permeability. This study underscores the significance of nanoparticle heterogeneity in determining particle fate in biological systems.

Abstract Female fecundity declines in a nonlinear manner with age during the reproductive years, even as ovulatory cycles continue, which reduces female fertility, disrupts metabolic homeostasis, and eventually induces various chronic diseases. Despite this, the aging‐related cellular and molecular changes in human ovaries that occur during these reproductive years have not been elucidated. Here, single‐cell RNA sequencing (scRNA‐seq) of human ovaries is performed from different childbearing ages and reveals that the activation of the pyroptosis pathway increased with age, mainly in macrophages. The enrichment of pyroptotic macrophages leads to a switch from a tissue‐resident macrophage (TRM)‐involve immunoregulatory microenvironment in young ovaries to a pyroptotic monocyte‐derived macrophage (MDM)‐involved proinflammatory microenvironment in middle‐aged ovaries. This remolded ovarian immuno‐microenvironment further promotes stromal cell senescence and accelerated reproductive decline. This hypothesis is validated in a series of cell and animal experiments using GSDMD‐KO mice. In conclusion, the work expands the current understanding of the ovarian aging process by illustrating a pyroptotic macrophage‐involved immune mechanism, which has important implications for the development of novel strategies to delay senescence and promote reproductive health.

Abstract Abnormal resumption of meiosis and decreased oocyte quality are hallmarks of maternal aging. Transcriptional silencing makes translational control an urgent task during meiosis resumption in maternal aging. However, insights into aging‐related translational characteristics and underlying mechanisms are limited. Here, using multi‐omics analysis of oocytes, it is found that translatomics during aging is related to changes in the proteome and reveals decreased translational efficiency with aging phenotypes in mouse oocytes. Translational efficiency decrease is associated with the N6‐methyladenosine (m6A) modification of transcripts. It is further clarified that m6A reader YTHDF3 is significantly decreased in aged oocytes, inhibiting oocyte meiotic maturation. YTHDF3 intervention perturbs the translatome of oocytes and suppress the translational efficiency of aging‐associated maternal factors, such as Hells, to affect the oocyte maturation. Moreover, the translational landscape is profiled in human oocyte aging, and the similar translational changes of epigenetic modifications regulators between human and mice oocyte aging are observed. In particular, due to the translational silence of YTHDF3 in human oocytes, translation activity is not associated with m6A modification, but alternative splicing factor SRSF6. Together, the findings profile the specific translational landscapes during oocyte aging in mice and humans, and uncover non‐conservative regulators on translation control in meiosis resumption and maternal aging.

Abstract Aims Prognosis of patients for human epidermal growth factor receptor 2 (HER2)‐negative breast cancer post neoadjuvant chemotherapy is not well understood. The aim of this study was to develop a novel pharmacophore‐based signature to better classify and predict the risk of HER2‐negative patients after anthracycline‐and/or taxane‐based neoadjuvant chemotherapy (NACT). Main methods Anthracycline and taxane pharmacophore‐based genes were obtained from PharmMapper. Drug‐targeted genes (DTG) related clinical and bioinformatic analyses were undertaken in four GEO datasets. Key findings We used 12 genes from the pharmacophore to develop a DTG score (DTG‐S). The DTG‐S classification exhibited significant prognostic ability with respect to disease free survival (DFS) for HER2‐negative patients who receive at least one type of neoadjuvant chemotherapy that included anthracycline and/or taxane. DTG‐S associated with a high predictive ability for pathological complete response (pCR) as well as for prognosis of breast cancer. Using the DTG‐S classification in other prediction models may improve the reclassification accuracy for DFS. Combining the DTG‐S with other clinicopathological factors may further improve its predictive ability of patients’ outcomes. Gene ontology and KEGG pathway analysis showed that the biological processes of DTG‐S high group were associated with the cell cycle, cell migration, and cell signal transduction pathways. Targeted drug analysis shows that some CDK inhibitors and PI3K‐AKT pathway inhibitors may be useful for high DTG‐S patients. Significance The DTG‐S classification adds prognostic and predictive information to classical parameters for HER2‐negative patients who receive anthracycline‐and/or taxane‐based NACT, which could improve the patients’ risk stratification and may help guide adjuvant treatment.

Abstract Triple‐negative breast cancer is the most aggressive subtype of breast cancer and the incidence of depression in breast cancer patients is high, which leading to worse survival and increased risk of recurrence. The effect of antidepressants on breast cancer patients remains contradictory, which might be due to variations in antidepression targets. Therefore, there is significant value to explore the antitumor potential of antidepressants and discover new therapeutic targets for breast patients. The authors screen antidepressant‐related oncogenes or suppressors by using siRNAs. After combining functional experiments with online database analysis, 5‐hydroxytryptamine receptor 1A (HTR1A is selected with antitumor potential in breast cancer cells in vivo and in vitro. RNA‐seq analysis and coimmunoprecipitation assays indicate that HTR1A interacts with TRIM21 and PSMD7 to inhibit the degradation of TβRII through the ubiquitin‐proteasome pathway, thereby inhibiting the transforming growth factor‐β (TGF‐β) canonical and noncanonical pathway. In addition, HTR1A is an independent predictive factor for breast cancer patients. The combined treatment of HTR1A agonists with demethylation drugs may significantly improve patient survival. It is of great significance to clarify the function and mechanism of the depression‐related gene HTR1A in breast cancer, which might provide a new approach for triple‐negative breast cancer patients.